Also, glucagon-like peptide-1 (GLP-1) receptor agonists are useful for weight reduction in obesity in the general population, and liraglutide has been given marketing authorization for this use [21]. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.